Skip to main content

Advertisement

Table 1 Baseline demographics and clinical characteristics (N = 409)

From: Assessment of efficacy and impact on work productivity and attendance after a mandatory switch to generic second-generation antihistamines: results of a patient survey in Norway

Sex, n (%)
   Female 271 (66.3%)
Age (y), n
   18-25 35
   26-35 67
   36-45 101
   46-55 122
   56-65 84
Diagnosis, %
   Pollen allergy 63.7
   Other nasal allergy 15.2
   Skin allergy/eczema 6.9
   Other 14.3
Pre-switch therapy, %
   Desloratadine 78.4
   Ebastine 16.0
   Fexofenadine 5.6
Post-switch therapy, %
   Cetirizine 64.7
   Loratadine 35.3